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to maintain systemic blood pressure5 and have been
demonstrated in critically ill patients with myocardial
infarction,6 cardiogenic shock,7 septic shock,8 adult respi-
ratory distress syndrome,9 heart failure,10,11 and acute kid-
ney failure.12 To date, several animal and human studies of
septic shock have suggested that endothelin release may be
pathologic13-18 or homeostatic.18,19 Increased plasma
endothelin levels have been demonstrated in patients
undergoing nonruptured abdominal aortic aneurysm
(AAA) repair with infrarenal20,21 and supraceliac aortic
cross-clamping,22 as well as in one animal model of
infrarenal aortic clamping and subsequent exsanguina-
tion.23 To date, however, there are no reports of the
endothelin response in patients undergoing repair of rup-
tured AAA. The aim of this study was to examine, for the
first time, perioperative changes in plasma levels of big ET-
1 and ET-1 in patients undergoing repair of ruptured
AAA. We hypothesized that hemorrhagic shock, ischemia,
and reperfusion would lead to increased synthesis and
secretion of endothelin, which would predispose to the
development of organ failure, one of the principal causes
of death in this group of patients.
METHODS
Patients. Fourteen consecutive patients (13 men and
1 woman of median age 74 years; range, 65-86) who
underwent repair of ruptured infrarenal AAA and survived
to at least 24 hours after surgery were prospectively stud-
ied. Lothian Research Ethics Committee approval was
Endothelin-1 (ET-1) is the most potent known vaso-
constrictor. It is principally secreted abluminally from vas-
cular endothelial cells but may enter the circulation if
concentrations are high at the endothelial cells–vascular
smooth muscle interface.1 ET-1 leads to vasoconstriction
in resistance vessels, especially the coronary, cerebral, and
renal circulation, by acting on ETA receptors in vascular
smooth muscle cells, and ETB receptors on vascular
smooth muscle and endothelial cells. Big ET-1 is the
immediate precursor of ET-1, and its conversion to bio-
logically active ET-1 by endothelin-converting enzymes
occurs mainly in the vessel wall.2,3 Big ET-1 is detectable
in the plasma for considerably longer than ET-1,4 and
increased plasma levels of big ET-1 are considered to rep-
resent increased ET-1 generation. Elevated plasma
endothelin levels may form part of a homeostatic response
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Background: Endothelin-1 (ET-1) is the most potent known vasoconstrictor. Elevated plasma levels have been demon-
strated in patients with myocardial infarction, cardiogenic and septic shock, and respiratory, heart, and kidney failure,
as well as in those undergoing elective abdominal aortic aneurysm (AAA) repair. However, endothelin levels have not
previously been examined in patients undergoing repair of ruptured AAA. We hypothesized that hemorrhagic shock,
lower torso ischemia, and reperfusion associated with ruptured AAA repair lead to increased synthesis and secretion of
ET-1, which, in turn, predispose to organ failure, one of the principal causes of death in this condition.
Methods: Fourteen patients were studied. Plasma levels of big ET-1 and ET-1 were measured immediately before oper-
ation and immediately before, 5 minutes, and 6 hours after aortic clamp release. 
Results: All patients survived for at least 24 hours after operation. Big ET-1 levels were above the normal range at
one or more sample points in all patients, and the ET-1 levels were above the normal range in all survivors and four
of five nonsurvivors. Five patients who died of organ failure had significantly lower big ET-1 levels at all sample
points and significantly lower ET-1 levels after 5 minutes of reperfusion when compared with survivors. Preoperative
ET-1 levels were significantly lower in eight patients who subsequently developed kidney failure than in six patients
who did not.
Conclusion: Contrary to our original hypothesis, these novel data demonstrate that patients with ruptured AAA in
whom fatal postoperative organ failure develops have significantly lower perioperative endothelin levels than survivors.
(J Vasc Surg 2001;33:1242-6.)
obtained. The median (range) delay between the onset of
symptoms of rupture and hospital admission was 5 (3-14)
hours. All patients had at least one documented episode of
hypotension (systolic blood pressure < 100 mm Hg)
before surgery. 
Operative methods. Ruptured AAA was defined by
the presence of fresh retroperitoneal blood at operation.
No patient had intraperitoneal rupture. All patients under-
went AAA repair under general anesthesia through a trans-
verse supraumbilical incision with infrarenal aortic
cross-clamping. No patient required suprarenal aortic
clamping. An aortoaortic graft was inserted in 10 patients,
an aortobifemoral graft in three, and an aortobiiliac graft
in one patient.
Sample collection and assay methods. Blood (8.2
mL) was obtained from an indwelling radial arterial line
and placed into ethylenediamine tetra-acetic acid (2.7 mL)
for estimation of hematocrit, and lithium heparin (5.5
mL) for estimation of big ET-1 and ET-1. Blood was sam-
pled immediately before the induction of anesthesia (sam-
ple A), immediately before aortic clamp release (sample
B), and 5 minutes (sample C) and 6 hours (sample D)
after aortic clamp release. Samples were placed immedi-
ately on ice and spun in a centrifuge within 30 minutes of
collection at 1400g for 30 minutes at 4°C. Plasma was
separated and stored at –70°C for later batch analysis.
Hematocrit was estimated in the routine hematology
laboratory with the fully automated Sysmex NE 8000 ana-
lyzer (Sysmex, Milton Keynes, UK). Plasma immunoreac-
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 6 Adam et al 1243
tive big ET-1 and ET-1 concentrations were measured by
use of an acetic acid extraction technique24 and a modified
commercial radioimmunoassay with rabbit antihuman big
ET-1 or ET-1 (Peninsula Laboratories Europe, St Helens,
UK). Sample extract was incubated with either big ET-1
or ET-1 antibody for 24 hours at 4°C. After incubation,
125-labeled big ET-1 (Peninsula Laboratories Europe) or
ET-1 (NEN Life Science Products, Boston, Mass) was
added, and incubation was continued for an additional 20
minutes at 4°C. Complexes were precipitated with
Amerlex donkey antirabbit antibody (Amersham Life
Sciences Limited, UK) and counted for radioactivity. The
lower limits of detection for the big ET-1 and ET-1 assays
are 1 pg/mL and 0.25 pg/mL, respectively. The normal
laboratory range for big ET-1 is 10 to 60 pg/mL, and for
ET-1 1.5 to 4.5 pg/mL.
Definitions of postoperative organ failure. Cardiac
failure was defined as arrhythmia requiring pharmacologic
treatment to maintain cardiovascular stability and/or sus-
tained periods of hypotension (mean arterial pressure ≤ 60
mm Hg) requiring fluid resuscitation and inotropic sup-
port. Respiratory failure was defined as hypoxia requiring
mechanical ventilatory support for more than 4 days.
Kidney failure was defined as elevated serum creatinine
level greater than or equal to 250 µmol/L and/or the
requirement for renal replacement therapy. Disseminated
intravascular coagulation was defined as clinical evidence
of hemorrhage accompanied by laboratory evidence of
thrombocytopenia, prolonged clotting times, hypofibrino-
Fig 1. Individual data points for big ET-1 immediately before
induction of anesthesia (sample A), immediately before release of
aortic clamp, (sample B), and 5 minutes (sample C), and 6 hours
(sample D) after aortic clamp release in 14 patients who under-
went operation for ruptured AAA. Survivors (n = 9) are repre-
sented by black squares and nonsurvivors (n = 5) by black circles.
Normal laboratory range for big ET-1 (10-60 pg/mL) is shown
by parallel horizontal lines. Mann-Whitney U test was used to test
whether medians of samples in survivors and nonsurvivors were
significantly different from each other at each sample point. A P
value less than .05 was regarded as statistically significant.
Fig 2. Individual data points for ET-1 immediately before induc-
tion of anesthesia (sample A), immediately before release of aor-
tic clamp, (sample B), and 5 minutes (sample C), and 6 hours
(sample D) after aortic clamp release in 14 patients who under-
went operation for ruptured AAA. Survivors (n = 9) are repre-
sented by black squares and nonsurvivors (n = 5) by black circles.
Normal laboratory range for ET-1 (1.5-4.5 pg/mL) is shown by
parallel horizontal lines. Mann-Whitney U test was used to test
whether medians of samples in survivors and nonsurvivors were
significantly different from each other at each sample point. A P
value less than .05 was regarded as statistically significant. NS,
Not significant.
genemia, and elevated levels of fibrin/fibrinogen degrada-
tion products. 
Statistical methods. The Mann-Whitney U test was
used to test whether the medians of samples in survivors
and nonsurvivors were significantly different from each
other and to examine whether there was a difference in
levels between patients who had postoperative organ fail-
ure compared with patients who did not. The Kruskal-
Wallis one-way analysis of variance was used to examine
whether assay levels changed significantly over the four
sampling points in survivors and nonsurvivors. A P value
of less than .05 was regarded as statistically significant.
RESULTS
Clinical data. All patients were admitted to the
intensive therapy unit after operation. All patients survived
for at least 24 hours after operation, but five (36%) died in
the postoperative period. Clinical and operative data for
survivors and nonsurvivors are summarized in Table I, and
postoperative complications are shown in Table II. 
Plasma levels of big ET-1 and ET-1. There was no
significant difference in hematocrit between survivors and
nonsurvivors at any of the sample points. The values of big
ET-1 and ET-1 in survivors and nonsurvivors are shown in
Figs 1 and 2, respectively. The big ET-1 level was above
the normal laboratory range at one or more sampling
points in all patients, and the ET-1 level was above the
normal range in all survivors and four of five nonsurvivors.
When compared with nonsurvivors, survivors had signifi-
cantly higher levels of big ET-1 at all four sampling points
and significantly higher levels of ET-1 after 5 minutes’
reperfusion than nonsurvivors. When compared with pre-
operative levels, there was a significant increase in big ET-
1 levels after 6 hours of reperfusion in survivors. In
nonsurvivors, there was a significant increase in ET-1 lev-
els between 5 minutes and 6 hours after reperfusion.
Preoperative ET-1 levels were significantly lower in eight
patients who subsequently had kidney failure (median,
3.72; range, 2.76-6.0 pg/mL) than in six patients who did
not (median, 5.89; range, 3.86-7.23 pg/mL; P = .02).
There was no significant difference in big ET-1 or ET-1
levels between patients who did and did not have cardiac
failure, respiratory failure, or disseminated intravascular
coagulation.
DISCUSSION
This study is the first to examine the relationship
between perioperative endothelin levels, organ failure, and
death in patients undergoing ruptured AAA repair. The
principal finding is that, contrary to our original hypothe-
sis, patients who died had significantly lower perioperative
endothelin levels than survivors. 
Previous studies of the endothelin response to lower
torso ischemia and reperfusion are few and contradictory.
Antonucci et al20 examined the effect of intraoperative
nifedipine infusion on endothelin-dependent renal vaso-
constriction in five patients undergoing nonruptured
infrarenal AAA repair and demonstrated a transient but
significant increase in plasma ET-1 and -2 levels at the end
of the period of aortic cross-clamping. The authors con-
cluded that nifedipine prevented the renal vasoconstrictor
response to endothelin because there was no significant
difference in creatinine clearance and glomerular filtration
rate after operation compared with before operation.
Fukuda et al21 measured arterial and iliac vein ET-1 levels
in seven patients undergoing elective aortic aneurysm
repair. There was no significant change in arterial ET-1
levels, but a significant increase in iliac vein ET-1 levels
occurred immediately after aortic clamp release and perfu-
sion of the first limb. Venous ET-1 levels showed a signif-
icant correlation with venous O2 content, pH, partial
pressure of oxygen O2, O2 saturation, and base excess sug-
gesting that ET-1 production occurred because of lower
limb ischemia. Lintott et al22 were the first to attempt to
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Table I. Clinical and operative data
Survivors (n = 9) Nonsurvivors (n = 5)
Median Range Median Range P value*
Preoperative
Duration of symptoms (h) 4 (3-14) 6 (5-12) NS
Serum creatinine level (µmol/L) 138 (82-176) 115 (77-183) NS
Intravenous fluid administration before clamping (L) 0.5 (0.2-5.5) 0.7 (0.1-1.0) NS
Intraoperative
Total operation time (min) 140 (75-240) 105 (75-200) NS
Aortic clamp time (min) 90 (40-185) 75 (55-135) NS
Measured blood loss (L) 4.0 (1.0-6.4) 3.3 (1.5-11.0) NS
Crystalloid and colloid administration (L) 3.4 (1.5-8.0) 3.8 (3.5-5.0) NS
pRBC administration (units) 8 (5-11) 8 (6-22) NS
FFP administration (units) 2 (2-6) 2 (2-12) NS
Platelet administration (bags)† 1 (1) 1 (0-1) NS
pRBC, Packed red blood cells (300 mL); FFP, fresh frozen plasma (300 mL).
*Mann-Whitney U test.
†One bag of platelet transfusion = 4 pooled units (250 mL).
examine the relationship between ET-1 levels and out-
come in 21 patients who required supraceliac and eight
who required infrarenal aortic clamping for repair of 
nonruptured aortic aneurysm. Unlike the studies by
Antonucci et al20 and Fukuda et al,21 plasma ET-1 was
undetectable during the period of aortic clamping and 30
minutes after aortic declamping. After 2 hours of reperfu-
sion, ET-1 levels were significantly higher in patients in
whom acute kidney failure developed after supraceliac
clamping, and at 8 hours, ET-1 levels were significantly
higher in the supraceliac clamp group compared with the
infrarenal clamp group. In a canine model of infrarenal
aortic clamping, Edwards et al23 failed to demonstrate a
significant increase in plasma ET-1 levels during hind limb
ischemia, but there was a significant increase during reper-
fusion and subsequent exsanguination. 
In this study, survivors had increased plasma endothe-
lin levels during the periods of lower torso ischemia and
reperfusion. Furthermore, more than half of the survivors
had increased endothelin levels before operation. There
was also a significant increase in endothelin levels after 6
hours of reperfusion in survivors and nonsurvivors. The
increased physiological insult of emergency ruptured AAA
repair may explain why, unlike previous studies of nonrup-
tured AAA repair, elevated endothelin levels were detected
before, during, and after operation.
It is interesting to speculate from these data that the
ET-dependent vasoconstrictor response to hemorrhagic
shock, ischemia, and reperfusion has a homeostatic and
protective role in ruptured AAA, in that patients who
manifest a good vasoconstrictor response (which is partly
due to endothelin) have a higher probability of survival
than those patients whose response is inferior. This
hypothesis would be in keeping with what most vascular
surgeons know intuitively: that is, intense vasoconstriction
(as well as “controlled” hypotension, aortic tamponade,
and the generation of a prothrombotic state) is one of the
principal mechanisms that allows patients with ruptured
AAA to reach the hospital in better clinical condition and
then undergo successful aneurysm repair. 
The reasons for low endothelin levels in nonsurvivors,
as well as those patients in whom acute kidney failure
developed, are not immediately obvious because ruptured
AAA repair is associated with many factors known to stim-
ulate endothelin synthesis and secretion: intraoperative
hemorrhage and hemodilution, hypoxia, and metabolic
acidosis, increased sympathetic discharge and cate-
cholamine release, increased cytokine and endotoxin
release, thrombin generation, and impaired renal excre-
tion. In this study, there was no apparent difference in the
duration of symptoms of rupture, severity of preoperative
shock, duration of lower torso ischemia or perioperative
hematocrit between survivors and nonsurvivors. Most
patients received renal-dose dopamine in the perioperative
period, but, unlike nifedipine, this has not been shown to
reduce plasma endothelin levels or maintain glomerular fil-
tration rate in patients undergoing major aortic surgery.25
Haynes et al26 reported a significant, and similarly
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 6 Adam et al 1245
unexpected, association between high plasma ET-1 levels
and survival in patients with cardiac arrest. They proposed
several explanations for their findings: poor peripheral
blood flow and local tissue acidosis may adversely affect
production and activity of ET-1, or lead to a local increase
in ET-1 that does not enter the circulation; increased
nitric oxide production may inhibit endothelin produc-
tion; and reduced pulsatile shear stress may lead to selec-
tive endothelial cell dysfunction. The low endothelin levels
demonstrated in nonsurvivors of ruptured AAA and car-
diac arrest26 may therefore be an early manifestation of
irreversible whole body hypoperfusion. Studies from this
department have shown that survivors and nonsurvivors of
ruptured AAA repair have elevated plasma levels of the
endothelial products, tissue plasminogen activator and
plasminogen activator inhibitor.27 These and present data
lend support to the hypothesis that selective endothelial
cell dysfunction may lead to downregulation of the
endothelin response in some patients with ruptured AAA,
and this may predispose to the development of fatal organ
dysfunction. 
Although most of the current literature concludes
that endothelin release has a pathologic role in critical 
illness,13-18 the findings of this study do not support the
hypothesis that an increased endothelin response predis-
poses to poor outcome in patients undergoing ruptured
AAA repair. By contrast, elevated perioperative endothelin
levels were associated with survival. Increased circulating
endothelin levels may occur as part of a homeostatic and
protective response to hemorrhage, ischemia, and reperfu-
sion in patients with ruptured AAA, or alternatively, low
endothelin levels may be an early marker of severe and irre-
versible whole body hypoperfusion in this group of patients.
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Table II. Postoperative complications
Survivors Nonsurvivors
(n = 9) (n = 5)
Cardiovascular
Cardiac failure 4 3
Myocardial infarction 1 —
Stroke 2 1
Critical lower limb ischemia 1 2
Respiratory
Respiratory failure 3 4
Acute respiratory distress — 1
syndrome
Pneumonia 6 5
Acute kidney failure 3 5
Disseminated intravascular 1 2
coagulation
Sepsis syndrome 1 2
Colon ischemia 1 —
Inotropic support
Adrenaline 2 3
Dopamine 7 4
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tance and Amanda Lee, Department of Public Health
Sciences, University of Edinburgh, for statistical assistance.
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